Blimp-1 is considered an essential regulator of the terminal differentiation of B cells into antibody-secreting plasma cells. We show here that Rag1 À/À mice reconstituted with fetal liver cells homozygous for a DNA-binding-deficient mutant of Prdm1 (the gene encoding Blimp-1) lack a defined plasma-cell compartment, yet show detectable amounts of all immunoglobulin isotypes. In vitro analysis revealed that Blimp-1 is not required for the initiation of antibody secretion but is essential for subsequent high immunoglobulin production. Blimp-1-independent differentiation was blocked at a preplasmablast stage characterized by decreased Pax5 expression and the activation of plasmacell genes. Analysis of Blimp-1-sufficient differentiation revealed a phase prior to Blimp-1 expression in which several genes normally repressed by Pax5 are re-expressed, suggesting that plasma-cell differentiation is initiated by the inhibition of Pax5 function. Our results indicate that full plasma-cell differentiation but not commitment to the plasma-cell fate requires the expression of functional Blimp-1.
INTRODUCTION
The differentiation of B cells into antibody-secreting cells (ASC) is a crucial component of the immune response. After encountering antigen, B cells undergo multiple rounds of division and have the ability to differentiate into plasmablasts, plasma cells, or memory B cells (Manz et al., 2005) . Plasmablasts are short-lived cycling ASC that are found in extrafollicular foci in peripheral lymphoid organs and resemble ASC generated after in vitro stimulation. In contrast, long-lived plasma cells are noncycling, found preferentially in the bone marrow, and derive predominantly from germinal centers (GC) (Manz et al., 2005) . The GC reaction also produces memory B cells that can rapidly differentiate into ASC after re-exposure to antigen.
A small number of transcription factors have been identified that guide the developmental program leading to ASC differentiation . Interestingly, the evidence to date suggests that this gene-regulatory network is dominated by transcriptional repression. One group of factors, including Pax5, Mitf, Bach2, and BCL6, are expressed in activated B cells and act predominantly by repressing differentiation (reviewed in . Pax5 represses genes associated with the stem cell and non-B lineage programs as well as a number of genes involved in ASC differentiation, including Prdm1 (the gene encoding B lymphocyte-induced maturation protein-1 [Blimp-1]), Xbp1, and Igj (J chain) (Delogu et al., 2006; Nera et al., 2006; Reimold et al., 1996; Rinkenberger et al., 1996) . BCL6 and Bach2 suppress ASC development in part by repressing Prdm1 (Ochiai et al., 2006; Tunyaplin et al., 2004) , whereas Mitf represses another key regulator of the ASC lineage, Irf4 (Lin et al., 2004) .
The molecular mechanism by which this repression cascade is overcome to allow ASC formation remains unclear, but it is known that differentiation and high immunoglobulin (Ig) secretion require IRF-4, XBP-1, and Blimp-1 (ShapiroShelef and Calame, 2005) . IRF-4 is present at low amounts throughout the B cell lineage, where it regulates isotype switching. Upon differentiation, IRF-4 expression markedly increases, which is essential for ASC formation and Ig secretion (Klein et al., 2006; Sciammas et al., 2006) . XBP-1 is an ubiquitously expressed transcription factor that directly controls aspects of the secretory pathway and is strongly induced in ASC by a combination of loss of Pax5-mediated gene repression and posttranscriptional control by the unfolded protein response (UPR) in the endoplasmic reticulum (Iwakoshi et al., 2003; Reimold et al., 1996) . Finally, ASC development is also critically dependent on Blimp-1, which has been termed the ''master regulator'' of plasma-cell differentiation.
Blimp-1 is expressed in ASC from human and mouse but is absent from earlier stages of B cell ontogeny (Angelin-Duclos et al., 2000; Kallies et al., 2004) . Many studies have contributed to the view that Blimp-1 is essential for Ig secretion and ASC development. Notably, ectopic Blimp-1 is sufficient to induce differentiation (Turner et al., 1994) , whereas the B cell-specific deletion of Prdm1 in mice demonstrates a requirement for Blimp-1 in the generation of a functional ASC compartment (Savitsky and Calame, 2006; Shapiro-Shelef et al., 2003) . Blimp-1-deficient mice show reduced, but not absent, serum Ig and display severely diminished antibody responses after immunization, whereas inactivation of Prdm1 in preformed plasma cells leads to the loss of this lineage (Shapiro-Shelef et al., 2003 . Gene-expression studies have shown that Blimp-1 is essential to extinguish many aspects of the mature B cell gene-expression program, including silencing of Myc (the gene encoding c-myc) and for the exit from the cell cycle characteristic of terminal differentiation (Shaffer et al., 2002) . Blimp-1 also directly binds and represses the promoters of Pax5, and potentially of Bcl6, thereby providing a mechanism by which its induction leads to ASC differentiation and loss of the B cell phenotype Vasanwala et al., 2002) .
To investigate the function of Blimp-1 in ASC, we introduced gfp into the Prdm1 locus (Kallies et al., 2004) . In heterozygous mice, quantitative changes of Blimp-1 expression, revealed by GFP, can be used to define distinct stages in ASC ontogeny, with intermediate expression associated with short-lived plasmablasts and high expression with long-lived plasma cells (Blink et al., 2005; Kallies et al., 2004) . We have now used this mouse strain to investigate the earliest stages of ASC formation and show here that Blimp-1 is dispensable for the initiation of the ASC differentiation program. We propose that downmodulation of Pax5 activity is the critical step that leads to the formation of a preplasmablast that is capable of secreting low amounts of Ig independent of Blimp-1 function. Blimp-1 is, however, essential for the progression from this earliest stage in ASC formation leading to the full manifestation of the transcriptional program and high-titer antibody production.
RESULTS

Low Ig Secretion Occurs
In Vivo in the Absence of Blimp-1 By using Prdm1 +/gfp mice, we have shown that Blimp-1 is expressed in all ASC (Kallies et al., 2004 ) and, at a lower level, in antigen-experienced T cells (Kallies et al., 2006 (Kallies et al., 2004) . The majority of these cells expressed the ASC marker Syndecan-1 (Synd-1 or CD138) and were low for CD19 ( Figure 1A ). In contrast, Prdm1 gfp/gfp mice lacked Synd-1 expression on GFP + cells suggesting an absence of ASC ( Figure 1A ). In these mice, however, we detected an increased population of GFP + Synd-1 À cells. Although a large fraction of these cells were T cells (Kallies et al., 2006) , up to 50% were CD19 + and belonged to the B cell lineage ( Figure 1A ).
ELISA analysis of serum showed that all Ig classes were detectable in Prdm1 gfp/gfp mice but were reduced to between 0.1%-10% of controls ( Figure 1B) . Immunoprecipitation of IgG from serum of these mice confirmed the low amounts of Ig determined by ELISA ( Figure 1C ). This Ig arose in Rag1 À/À mice reconstituted with hematopoietic cells that were uniformly deficient for the Blimp-1 DNAbinding domain, so these data demonstrated that some Ig secretion occurred in the absence of wild-type Blimp-1. 
Rag1
À/À mice ( Figure 1D ). We were, however, unable to locate any IgA-secreting cells in the lamina propria despite the presence of IgA-switched B cells in intestinal follicles ( Figure 1E ). These experiments demonstrated through a number of approaches that Prdm1 gfp/gfp mice lacked bona fide ASC but contain cells that were capable of low-titer Ig secretion.
Severely Impaired ASC Differentiation in Immunized Blimp-1 Mutant Mice We have shown previously that T cell-dependent (NP-KLH) and -independent (LPS) antigens induce a transient plasmablast population with lower Blimp-1 expression than that of mature plasma cells (Kallies et al., 2004 Figure S1A in the Supplemental Data available online).
In a second approach, we examined the development of ASC in response to immunization with the T-dependent antigen NP-KLH. In this model, NP-specific ASC can be found initially in the spleen and appear at later time points in the GFP high plasma-cell population in the spleen and bone marrow (Blink et al., 2005; Kallies et al., 2004 Figure S1B ). These data again provide evidence for the induction of low specific Ig secretion in the absence of Blimp-1.
ASC Differentiation Is Induced but Abortive in the Absence of Blimp-1 In Vitro
To further investigate the dependence of Ig production on Blimp-1, purified resting splenic B cells were cultured in conditions that mimic T cell help (anti-CD40+IL4+IL5) or microbial stimuli (LPS) for 4 days and then analyzed for ASC phenotype and Ig production Kallies et al., 2004) . As expected, the Prdm1 +/gfp cultures contained GFP + cells (Figure 2A ), which we have shown to 
Initiation of the Plasma-Cell Gene-Expression Program in the Absence of Blimp-1
To examine whether B cells cultured in anti-CD40+IL4+IL5 were able to regulate genes associated with ASC differentiation in the absence of functional Blimp-1, we sorted GFP + and GFP À cells according to the gates depicted in Figure 3A and performed semiquantitative RT-PCR analysis. Surprisingly, we found that GFP + Prdm1 gfp/gfp ASC had downregulated Pax5 transcription and initiated expression of Igj and Xbp1, suggesting that early steps of ASC differentiation had occurred independently of Blimp-1 ( Figure 3F ). Similarly, the splicing of IgH mRNA into the secreted and membrane forms was regulated appropriately in both Blimp-1-sufficient and mutant GFP + Synd-1
cells, however, failed to upregulate
Irf4 ( Figure 3F ). expression reduced by 62.5% versus 84.1%, respectively, Figure 4A ). In agreement with this, real-time RT-PCR confirmed the upregulation of the Pax5-repressed genes Igj and Xbp1 in the Blimp-1 mutant ASC, although again this effect was less pronounced than in Prdm1 +/gfp ASC ( Figure 4A ). Importantly, the spliced form of Xbp1 was also detected, suggesting the expression of functional XBP-1 in Blimp-1 mutant ASC ( Figure 4C ). Suppression of Pax5 protein expression was also evident, as was increased production of IgM and Igk ( Figure 4B ). Thus, Blimp-1 mutant B cells, while not capable of differentiating to fully secretory ASC, initiated the differentiation pathway that resulted in some Ig secretion in vitro. IRF-4 has been shown to be essential for ASC differentiation, so we speculated that the lack of Irf4 upregulation in Prdm1 gfp/gfp B cells was responsible for their failure to differentiate into high-titer Ig-secreting cells. However, retroviral overexpression of IRF-4 in Prdm1 gfp/gfp B cells was not sufficient to substantially increase Ig secretion, whereas, as expected, enforced expression of Blimp-1 resulted in markedly elevated Ig production ( Figure 4D ). Ectopic expression of IRF-4 also failed to induce Igj, Xbp1, or endogenous Irf4 in the absence of Blimp-1, whereas forced expression of Blimp-1 in Prdm1 gfp/gfp B cells resulted in increased amounts of Igj and Xbp1 but was, surprisingly, not sufficient to induce Irf4 ( Figure 4E ). These data suggest that Blimp-1 regulates factors other than Irf4 to promote ASC differentiation.
Suppression of Pax5 Activity in B Cells Precedes Blimp-1 Expression
The observation that ASC differentiation was initiated in the absence of functional Blimp-1 was surprising and led us to examine the early events in this process upstream of Blimp-1. Pax5 is an essential regulator that maintains B cell identity and suppresses ASC differentiation (Delogu et al., 2006; Nera et al., 2006) , so the downregulation of Pax5 represented an attractive candidate as the differentiation-initiating event. It has been proposed that Pax5 is a direct target of Blimp-1-mediated repression . The data described above, however, suggested that the initial downregulation of Pax5 was independent of Blimp-1. To examine Pax5 activity in several different B cell populations, we made use of the recent finding that a number of target genes repressed by Pax5, including those encoding the receptor tyrosine kinase Flt3, the adhesion molecule embigin (Delogu et al., 2006; Holmes et al., 2006) , and the inhibitor receptor PD-1 (Nutt et al., 1998) , are re-expressed upon silencing of Pax5 during B cell differentiation. Freshly isolated resting splenic Prdm1 +/gfp B cells expressed very low amounts of Flt3, embigin, and PD-1 ( Figure 5A and data not shown). However, as early as 24 hr after culture in the presence of LPS or anti-CD40+IL4+IL5, expression of all three molecules was readily detected on a subset of stimulated B cells (data not shown). After 3 days, the majority of LPS-stimulated GFP À B cells expressed Flt3, embigin, and PD-1, whereas a smaller fraction of anti-CD40+IL4+IL5-stimulated GFP À B cells stained positive for these molecules ( Figure 5A and data not shown). Importantly, the expression of these genes occurred in GFP À cells, suggesting that derepression of Pax5 target genes preceded Blimp-1 induction. Figure 3A . This interpretation was confirmed by the observation that activated Prdm1 gfp/gfp B cells also expressed these Pax5 target genes ( Figure 5B ). To determine whether the release of Pax5-mediated gene repression occurred in vivo, we examined embigin expression in various mature B cell subsets in naive and immunized mice. Embigin staining was found constitutively on myeloid and splenic T cells whereas only a minority of splenic B cells was embigin + ( Figure 5C ). A more detailed analysis of the splenic B cell compartment revealed that embigin was restricted to marginal zone (MZ) B cells, whereas follicular B cells were embigin À ( Figure 5C ). In line with their predisposition to ASC differentiation (Fairfax et al., 2007) , peritoneal B1 B cells were uniformly embigin + ( Figure 5C ). The proportion of the embigin + B cell population in spleen increased slightly after immunization with NP-KLH ( Figure 5C ), but the representation of embigin + cells was markedly increased among the PNA high GC cells and essentially all ASC were embigin + ( Figure 5C ). Similar results were obtained with PD-1 and Flt3, although Flt3 was subsequently silenced in ASC by a distinct mechanism ( Figure 5A and data not shown).
The re-expression of Pax5-suppressed genes prompted us to examine whether the expression of Pax5-activated genes, including Cd23 (Visan et al., 2003) , Cd19, Cd79a (Nutt et al., 1998) , and Blnk (Schebesta et al., 2002) were also modulated in activated B cells. Indeed, we found that CD23 had a complementary expression profile to embigin, with low expression on peritoneal B1 and GC B cells when compared to splenic B cells, and that CD23 was markedly decreased when B cells were activated in vitro ( Figure 5D ). Molecular analysis further demonstrated that downregulation of Cd79a and Blnk occurred in Cd19Cre mice showed strongly reduced, but clearly detectable, amounts of serum Ig and a low Ig secretion in vitro (Shapiro-Shelef et al., 2003) . This and the failure of these mice to mount an antigen-specific Ig response led to the conclusion that Blimp-1 is absolutely required for ASC differentiation (Shapiro-Shelef et al., 2003) . However, the incomplete Cre-mediated deletion of the conditional allele in that study made it difficult to determine whether Blimp-1-independent differentiation pathways existed. The model for Blimp-1 deficiency presented here, via Rag1 À/À mice reconstituted with Prdm1 gfp/gfp fetal liver stem cells, has two principle advantages. First, because Rag1 À/À mice lack endogenous B cells and serum Ig, any detectable Ig must derive from the Blimp-1 mutant B cells. The second advantage of our mouse model is the ability to track Blimp-1 expression by means of GFP (Kallies et al., 2004 (Kallies et al., , 2006 , which enables us to detect cells with an active Prdm1 locus on a single-cell basis in the presence or absence of functional Blimp-1 protein and to track defects in these B cells to a distinct developmental state.
By a number of criteria, we have shown here that Prdm1 gfp/gfp mice have low titers of serum Ig. This raised the question of whether this Ig was produced by a rare, fully functional, ASC population lacking Blimp-1 or was the result of low secretion by a Blimp-1-independent stage of ASC differentiation. An earlier study suggested that B1 B cells are capable of secreting Ig in the absence of Blimp-1 expression (Tumang et al., 2005) . However, recent studies have shown that Ig secretion from B1 cells crucially depends on, and is paralleled by, Blimp-1 expression (Fairfax et al., 2007; Savitsky and Calame, 2006) , indicating that full ASC differentiation from all B cell subsets depends on Blimp-1. Our data demonstrate the existence of a Blimp-1-independent phase of ASC differentiation, and we propose the term ''preplasmablast'' to driven by homeostatic mechanisms resulting from the low titers of natural antibody as previously proposed (Agenes and Freitas, 1999) . In addition to Blimp-1, XBP-1 and IRF-4 are two transcription factors known to be essential for ASC generation (Mittrucker et al., 1997; Reimold et al., 2001 ). Whereas Xbp1 is considered to be downstream of Blimp-1 , we show here that initial induction of Xbp1 is largely the result of loss of Pax5-mediated suppression, and we propose that the subsequent high expression of Xbp1 is a consequence of the UPR rather than being directly mediated by Blimp-1. In keeping with this, enforced expression of XBP-1 in (Stephenson et al., 2006) . In summary, while initiation of ASC differentiation is Blimp-1 independent, completion of this process depends on the coordinate expression of all three factors, Blimp-1, IRF-4, and XBP-1. A key question in the study of the transcriptional events that control ASC differentiation is how the stable longterm transcriptional program of B cells is silenced and replaced by the fundamentally different program that governs the plasma-cell fate. The current consensus is that this process is orchestrated by the direct repression of the B cell fate by Blimp-1 (Shapiro-Shelef and Calame, 2005) . The data presented here, however, challenge this concept and provide a significant revision to this model by identifying a central role for the B cell maintenancefactor Pax5.
Mature B cells express Pax5 and ASC differentiation is paralleled by its downregulation (Delogu et al., 2006) . Pax5 is known to regulate Ig production by repressing Igh (Linderson et al., 2004) and Igk (Roque et al., 1996) transcription as well as expression of Xbp1 (Reimold et al., 1996) and Igj (Rinkenberger et al., 1996) . Loss of Pax5 is sufficient to induce IgM secretion and Blimp-1 expression (Delogu et al., 2006; Nera et al., 2006) . A limitation of previous studies examining ASC differentiation was that they were conducted on Blimp-1-sufficient B cells, thereby making it impossible to separate the stages in differentiation that were solely dependent on Pax5 repression from subsequent steps that were dependent on Blimp-1 induction. Microarray studies performed on wild-type and Blimp-1-deficient B cells stimulated under conditions that support ASC differentiation are again of limited utility in addressing this question, because the majority of cells in the cultures remain undifferentiated B cells and thus are not likely to identify Blimp-1-independent gene-regulatory processes occurring in a subset of cells.
By using the Blimp-1 GFP reporter, we show here that Pax5 is rapidly extinguished in Blimp-1 + cells, a finding compatible with Pax5 being a direct target of Blimp-1 repression . However, we further demonstrate that the early phase of Pax5 downregulation occurs independently of Blimp-1, because both GFP + Prdm1 gfp/gfp and Prdm1 +/gfp preplasmablasts showed similar Pax5 downregulation and induction of Pax5-repressed genes, suggesting that other factors are involved in this process. In support of this conclusion, ectopic expression of Blimp-1 in some models did not silence Pax5, suggesting that repression of the Pax5 locus depends on factors other than Blimp-1 (Sciammas and Davis, 2004) .
To further examine the role of Pax5 in initiating the transcriptional cascade leading to ASC, we took advantage of the recent comprehensive reports of Pax5-repressed genes (Delogu et al., 2006; Nera et al., 2006) . Three molecules, Flt3, embigin, and PD-1, were particularly advantageous because they are cell-surface molecules whose expression is repressed by Pax5 upon B cell commitment, but reactivated during ASC differentiation. Examination of the expression kinetics of these proteins demonstrated that they were induced before, and thus in the absence of, Blimp-1. The simultaneous derepression of three independent Pax5 target genes provides compelling evidence that Pax5 activity is modulated prior to Blimp-1 induction in ASC differentiation. Importantly, we also found evidence for the Blimp-1-independent regulation of Pax5 activity by examining the expression of the Pax5-activated target genes Cd23, Cd79a, and Blnk (Nutt et al., 1998; Schebesta et al., 2002; Visan et al., 2003) . All three genes were distinctly downregulated in the Flt3 + fraction before the onset of Blimp-1 expression. These changes were, however, specific for individual genes: the expression of another Pax5-activated gene Cd19 was found to be unchanged in Flt3 + B cells. Interestingly, we found that some in vivo B cell populations, including a large fraction of MZ and GC B cells, as well as B1 cells, resembled Flt3 + B cells in vitro in that they showed altered expression of Pax5 target genes. This poised gene-expression profile may explain the rapid kinetics by which both B1 and MZ B cells differentiate into ASC in vitro (Fairfax et al., 2007) .
The suppression of Pax5 activity was independent of changes in its protein expression or in vivo DNA binding, raising the possibility that changes in the expression or activity of other transcription factors during B cell activation alter Pax5 activity. Indeed, it has been shown that Pax5 function is modulated by the relative abundance of Id2 (Gonda et al., 2003) and PU.1 (Linderson et al., 2004) . We propose that a similar mechanism regulates the initiation of ASC differentiation, although the identity of the inhibitory factor operating on Pax5 is currently unknown.
Over the past few years a model of the transcriptional regulation of the terminal differentiation of B cells to the ASC fate has been proposed. The central point of this model is the mutually antagonistic interactions between a number of transcriptional repressors, including Pax5, BCL6, and Blimp-1 (Shapiro- . Although this model describes the delineation and transcriptional stability of the B cell and ASC states, it does not adequately explain how the mutual transcriptional repression is lifted to allow differentiation. The data presented here provide a number of insights into the earliest events in this process and allow us to extend the current model ( Figure 7) . We propose that in the resting state, B cells stably express Pax5, which represses the ASC program. Upon cell activation, Pax5 function is modified, through an unknown mechanism, altering the expression of a number of Pax5 target genes important for the ASC fate. We propose that this event initiates the ASC program and generates the preplasmablast stage, which is characterized by downregulation of Pax5, low Ig secretion, and Blimp-1 induction. Blimp-1 then silences Pax5 transcription, and thus the B cell program, by a classical feedback inhibition mechanism. Although the available evidence suggests that the preplasmablast is a transient step in normal differentiation, cells accumulate at this point in the absence of Blimp-1. This model provides a framework to investigate the interaction of Pax5 and Blimp-1 in controlling the B cell and ASC fates, respectively, as well as to investigate the roles played by other molecules, in particular OBF-1, Bach2, BCL6, and IRF-4, in the process.
EXPERIMENTAL PROCEDURES
Transplantation of Fetal Liver Cells E14 embryos from intercrossed Prdm1 +/gfp (C57BL/6 Ly5.2) mice were genotyped and fetal liver chimeras generated in Rag1 À/À (C57BL/6
Ly5.1) recipients and analyzed after 8 weeks as described (Kallies et al., 2004) . All animal experiments were conducted according to the protocols approved by the Melbourne Health animal ethics committee.
Flow Cytometry mAb against CD19 (1D3), B220 (RA3-6B2), Ly5.2 (ALI-4A2), Flt3 (A2F10.1), IgM (331.12), CD5 (Ly-1), and CD21 (7G6) were purified from hybridoma supernatant and conjugated in the author's laboratory. Anti-Synd-1 (281-2), PD-1 (J43), and CD23 (B3B4) were obtained from BD Biosciences, and peanut agglutinin (PNA) was from Vector Laboratories. The rat embigin mAb will be described elsewhere (S.L.N., unpublished). Cells were analyzed on an LSR and cell sorting was carried out on a DiVa flow cytometer (BD Biosciences).
ELISA and ELISpot Assay
Serum and supernatant Ig amounts were measured by ELISA as described previously . Mucosal IgA was isolated from fecal samples by the following procedure. 1 ml of 0.1 mg/ml soybean trypsin inhibitor (Sigma-Aldrich) in PBS was added per 0.1 g of feces, then vortexed in a mini-bead beater for 10 s at 2500 rpm. Debris was removed by centrifugation and supernatants were assayed for IgA by ELISA. ELISpot assays were performed on MultiScreen-HA filter plates (Millipore). Cells were incubated for 4 hr at 37 C on precoated 96-well filter plates and developed with the appropriate enzymeconjugated secondary antibodies and substrates.
Immunohistochemistry Small intestines were harvested into OCT (Sakura Finetek) and frozen on dry ice. 5 mm sections were cut onto polylysine-coated slides, fixed in acetone, rehydrated in PBS, and blocked with PBS/10% FCS before staining with anti-mouse IgA-HRP. Staining was visualized with diaminodenzidine (Sigma-Aldrich) and counterstained with haematoxylin.
In Vivo Induction of ASC Mice were injected intravenously with 3 mg E. coli LPS (O111:B4, Sigma-Aldrich) and analyzed at days 3 and 7. Immunization was with a single intraperitoneal injection of 100 mg 4(hydroxy-3)-nitrophenyl (NP) coupled to keyhole limpet hemocyanin (KLH) in the ratio of 13:1, and IgG1 ASC activity in 500 sorted GFP + populations was determined with NP-specific ELISpot as described (Smith et al., 1997) .
In Vitro Cell Culture Naive splenic B cells were purified by Percoll gradient centrifugation and B220 magnetic bead purification (Miltenyi Biotec) as described . Purified cells were cultured at 1 3 10 5 /ml with optimal concentrations of CD40 antibody (1C10, 10 mg/ml), IL4 (500 U/ml, R&D Systems), and IL5 (2 ng/ml, R&D Systems). 4 3 10 5 cells/ml were used for LPS (20 mg/ml) stimulation.
Western Blotting and Immunoprecipitation
The Pax5 mAb was generated in rats by immunization with a purified GST-Pax5 fusion protein consisting of amino acids 154-284 of mouse Pax5. mAbs were screened by immunoblotting via Pax5 À/À and wildtype pro-B cell lines (Nutt et al., 1998) . Reactivity with an endogenous protein of the appropriate size for Pax5 ($50 kDa) protein was specifically detected for clone 1H9. The Blimp-1 mAb and immunoblotting was as previously described (Kallies et al., 2004 and fixed with 0.5% formaldehyde. 2.5 3 10 6 cells were used for each
ChIP experiment as described (Holmes et al., 2006) . 5 3 10 6 wild-type and Pax5 À/À pro-B cells (Nutt et al., 1998) were used as controls. Irf4 5 0 -GGACTACAATCGTGAGGAGGAC, 5 0 -ACGTCACAGGACATTG ATATGG. Detection of the spliced form of Xbp1 was as described (Iwakoshi et al., 2003) . Real-time PCR was carried out as described (Holmes et al., 2006) with the products being quantified in relation to Hprt amounts.
RT-PCR Analysis
Retroviral Infection
The MSCV-IRF4-Puro and MSCV-Puro retroviral vectors were as reported (Tamura et al., 2005) . Transfection of Phoenix cells and subsequent spin infection was performed as described (Corcoran et al., 2005) . Purified splenic B cells were activated with anti-CD40+IL4+IL5 for 40 hr (as described above) and used for spin infections before being placed in the same medium. After overnight culture, transduced B cells were selected by puromycin (4 mg/ml) for 48 hr. Surviving cells were then counted and analyzed by flow cytometry or recultured in media at 1 3 10 5 cells/ml overnight, and the supernatant was assayed for Ig.
Supplemental Data
One figure is available at http://www.immunity.com/cgi/content/full/ 26/5/555/DC1/.
